- Report
- December 2024
- 150 Pages
Global
From €5295EUR$5,950USD£4,661GBP
- Report
- July 2025
- 150 Pages
Global
From €5295EUR$5,950USD£4,661GBP
- Report
- October 2025
- 198 Pages
Global
From €3155EUR$3,545USD£2,777GBP
€3505EUR$3,939USD£3,085GBP
- Report
- August 2025
- 194 Pages
Global
From €3155EUR$3,545USD£2,777GBP
€3505EUR$3,939USD£3,085GBP
- Report
- October 2025
- 281 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Report
- October 2025
- 364 Pages
Global
From €5206EUR$5,850USD£4,582GBP
- Report
- October 2025
- 250 Pages
Global
From €3995EUR$4,490USD£3,517GBP
- Report
- August 2025
- 189 Pages
Global
From €3155EUR$3,545USD£2,777GBP
€3505EUR$3,939USD£3,085GBP
- Clinical Trials
- April 2025
- 80 Pages
Global
From €1424EUR$1,600USD£1,253GBP
€1780EUR$2,000USD£1,567GBP
- Clinical Trials
- April 2025
- 90 Pages
Global
From €1780EUR$2,000USD£1,567GBP
€2225EUR$2,500USD£1,958GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €890EUR$1,000USD£783GBP
€1112EUR$1,250USD£979GBP
- Report
- December 2024
- 84 Pages
Global
From €2812EUR$3,160USD£2,475GBP
€3515EUR$3,950USD£3,094GBP
- Report
- April 2025
- 183 Pages
Global
From €4004EUR$4,500USD£3,525GBP
- Report
- October 2025
- 150 Pages
Global
From €3426EUR$3,850USD£3,016GBP
- Report
- January 2025
- 200 Pages
Global
From €4445EUR$4,995USD£3,913GBP
- Report
- August 2025
- 120 Pages
United States
From €3515EUR$3,950USD£3,094GBP
- Report
- November 2018
- 147 Pages
Global
From €2447EUR$2,750USD£2,154GBP
- Report
- October 2023
- 145 Pages
Global
From €2803EUR$3,150USD£2,467GBP
- Report
- October 2023
- 145 Pages
Global
From €2803EUR$3,150USD£2,467GBP
- Report
- July 2023
- 135 Pages
Global
From €5339EUR$6,000USD£4,700GBP
€6674EUR$7,500USD£5,875GBP

Opioid Use Disorder (OUD) is a type of addiction disorder that is characterized by the compulsive use of opioids, such as heroin, morphine, and prescription painkillers. OUD is a serious public health issue, with an estimated 2.1 million people in the United States suffering from the disorder. OUD is associated with a range of physical and psychological health problems, including an increased risk of overdose, infectious diseases, and mental health issues. Treatment for OUD typically involves a combination of medication-assisted treatment (MAT) and psychosocial interventions. MAT involves the use of medications, such as buprenorphine and methadone, to reduce cravings and withdrawal symptoms. Psychosocial interventions include cognitive-behavioral therapy, motivational interviewing, and 12-step programs.
Companies in the OUD market include Indivior, Alkermes, Orexo, and Braeburn Pharmaceuticals. Show Less Read more